{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:26:14Z","timestamp":1772223974806,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40257-018-0376-3","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T07:09:37Z","timestamp":1533193777000},"page":"899-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients"],"prefix":"10.1007","volume":"19","author":[{"given":"Macartney","family":"Welborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby L.","family":"Kubicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"5","key":"376_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616\u201322.","journal-title":"J Clin Oncol"},{"key":"376_CR2","doi-asserted-by":"publisher","unstructured":"Tremelimumab. Drugs R D. 2010;10(2):123\u201332. https:\/\/doi.org\/10.2165\/11584530-000000000-00000 .","DOI":"10.2165\/11584530-000000000-00000"},{"issue":"1","key":"376_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81\u20138.","journal-title":"J Hepatol"},{"key":"376_CR4","first-page":"1767","volume":"9","author":"B Comin-Anduix","year":"2016","unstructured":"Comin-Anduix B, Escuin-Ordinas H, Ibarrondo FJ. Tremelimumab: research and clinical development. Onco Targets Ther. 2016;9:1767\u201376.","journal-title":"Onco Targets Ther."},{"issue":"5","key":"376_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/j.seminoncol.2010.09.010","volume":"37","author":"A Ribas","year":"2010","unstructured":"Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. 2010;37(5):450\u20134.","journal-title":"Semin Oncol"},{"key":"376_CR6","unstructured":"Arce vargas F, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018;33(4):649\u201363.e4."},{"issue":"40","key":"376_CR7","doi-asserted-by":"crossref","first-page":"67129","DOI":"10.18632\/oncotarget.18004","volume":"8","author":"M He","year":"2017","unstructured":"He M, Chai Y, Qi J, et al. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget. 2017;8(40):67129\u201339.","journal-title":"Oncotarget."},{"key":"376_CR8","unstructured":"Clinicaltrials.gov. \u201cClinical trials involving tremelimumab.\u201d 13 February, 2018. http:\/\/www.clinicaltrials.gov\/ct2\/results?term=tremelimumab&Search=Apply&recrs=a&recrs=d&age_v=&gndr=&type=&rslt= . Accessed 18 Jul 2018."},{"issue":"4","key":"376_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","volume":"25","author":"AM Joshua","year":"2015","unstructured":"Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015;25(4):342\u20137.","journal-title":"Melanoma Res"},{"issue":"1","key":"376_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Wolchok JD, Yosipovitch G, K\u00e4hler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"376_CR11","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100(8):4712\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"376_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.18632\/oncotarget.323","volume":"2","author":"KT Byrne","year":"2011","unstructured":"Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684\u201394.","journal-title":"Oncotarget."},{"issue":"7","key":"376_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773\u201381.","journal-title":"J Clin Oncol"},{"issue":"9","key":"376_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","volume":"72","author":"JM Subramaniam","year":"2012","unstructured":"Subramaniam JM, Whiteside G, Mckeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293\u20138.","journal-title":"Drugs."},{"issue":"3","key":"376_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi BA. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299\u2013308.","journal-title":"Lancet Oncol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-018-0376-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0376-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0376-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T05:26:58Z","timestamp":1604726818000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-018-0376-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["376"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0376-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"assertion":[{"value":"2 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Macartney Welborn, Shelby L. Kubicki, Naveen Garg, and Anisha B. Patel have no conflicts of interest directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}